Search Results - "Ge, Liner"

Parametric and non-parametric Poisson regression for modelling of the arterial input function in positron emission tomography by Matheson, Granville J., Ge, Liner, Zhang, Mengyu, Sun, Bingyu, Tu, Yuqi, Zanderigo, Francesca, Forsberg Morèn, Anton, Ogden, R. Todd

“…Full quantification of Positron Emission Tomography (PET) requires an arterial input function (AIF) for measurement of certain targets, or using particular…”
Get full text

A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma by Bose, Sminu (Sam), Ge, Liner, Lee, Shing M, Van Tine, Brian Andrew, Agulnik, Mark, Weiss, Mia C., Lacuna, Kristine Peregrino, Sender, Naomi, Sta Ana, Sarah, Hsu, Frank J., Schwartz, Gary K., Ingham, Matthew

“…11565 Background: Immune checkpoint inhibitors have limited efficacy in soft tissue sarcoma (STS) due to insufficient T-cell activation and infiltration by…”
Get full text

A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma by Ingham, Matthew, Lee, Shing, Van Tine, Brian A, Choy, Edwin, Oza, Jay, Doshi, Sahil, Ge, Liner, Oppelt, Peter, Cote, Gregory, Corgiat, Brian, Sender, Naomi, Sta Ana, Sarah, Panchalingam, Lavan, Petricoin, Emmanuel, Schwartz, Gary K

“…To evaluate sitravatinib, an inhibitor of multiple receptor tyrosine kinases (RTK), for the treatment of well-differentiated/dedifferentiated liposarcoma…”
Get full text

ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma by Lacuna, Kristine Peregrino, Lee, Shing M, Ge, Liner, Druta, Mihaela, Conley, Anthony Paul, Keohan, Mary Louise, Agulnik, Mark, Burgess, Melissa Amber, Chalmers, Anna Weinberg, D'Amato, Gina Z., Powers, Benjamin, Seetharam, Mahesh, Siontis, Brittany L, Weiss, Mia C., Bose, Sminu (Sam), Sheikh, Tahir, Piekarz, Richard, Schwartz, Gary K., Ingham, Matthew

“…11531 Background: Conventional chondrosarcoma (cCS) is the 2nd most common primary bone tumor and is resistant to chemotherapy and radiation. IDH1/2 mutations…”
Get full text

MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies by Manji, Gulam Abbas, Labadie, Brian William, Lee, Shing M, Pellicciotta, Ilenia, Ge, Liner, Sta Ana, Sarah, Sender, Naomi, Ross, Isabelle, Wong, Winston, Raufi, Alexander G

“…45 Background: Autophagy, a catabolic cell survival process, is upregulated when cancer cells undergo MEK inhibition (MEKi) in preclinical models of pancreas…”
Get full text

Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma by Manji, Gulam A, Lee, Shing, Del Portillo, Armando, May, Michael, Ana, Sarah Sta, Alouani, Emily, Sender, Naomi, Negri, Tiffany, Gautier, Katarzyna, Ge, Liner, Fan, Weijia, Xie, Mengyu, Sethi, Amrita, Schrope, Beth, Tan, Aik Choon, Park, Haeseong, Oberstein, Paul E, Shah, Manish A, Raufi, Alexander G

“…Combining immune checkpoint blockade (ICB) with chemotherapy improves outcomes in patients with metastatic gastric and gastroesophageal junction (G/GEJ)…”
Get more information